| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Ardent Health, Inc.$10.75
0 (0%)
Market Cap
1.34 B
EPS
0.97
P/E Ratio
9.79 $
Value Trade
15.17 M
SEC Financials
Q1 2026Dilution Risk
Revenue
1.60 B
Operating CF
-60.22 M
Total Assets
5.25 B
Total Liabilities
3.52 B
Equity
1.34 B
%
Week
%
1 Month
%
3 Month
%
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
609.69 M
Monthly Burn
20.07 M
Runway
27.7 mo
Burn Trend
SEC Filing
May 6, 2026
Overview
Volume
413.48 K
52 Week Range
8.07 - 15.48
% held by Insiders
84.42 %
% held by Institutions
14.37 %
Enterprise Value
3.35 B
Total Shares
143.44 M
Short %
20.64 %
Float Shares
23.52 M
Company Description
locked
Upcoming Catalyst
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ARDT
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
ARDT Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-ARDT
Aug 4, 2026Ardent Health Reports Second Quarter 2026 Results
Ardent Health, a prominent healthcare provider, has released its financial results for the second quarter of 2026, showing positive growth compared to the previous year. The company focuses on serving mid-sized urban communities across the U.S. and has reported an increase in operational metrics. Detailed comparisons and definitions of metrics are provided in the accompanying press release.
Read more →-ARDT
Jul 23, 2026Ardent Health surpasses 1 million patient encounters supported by ambient AI
Ardent Health has achieved a major milestone by surpassing 1 million patient encounters supported by Ambience Healthcare's ambient AI platform. This achievement highlights the organization's commitment to reducing clinician burnout and enhancing the overall provider experience. The technology is utilized in 87% of ambulatory encounters, showcasing its widespread adoption among Ardent-affiliated clinicians.
Read more →-ARDT
Jul 17, 2026Ardent Health Announces Second Quarter 2026 Results Conference Call and Webcast Date
Ardent Health has announced the date for its second quarter 2026 results conference call. The financial results will be released after market close on August 4, 2026, followed by a call on August 5, 2026, at 10 a.m. ET. This event will include a review of the results and a Q&A session.
Read more →-ARDT
Jun 3, 2026▼ -15.5%on this news
Ardent Health to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
Ardent Health is set to participate in the Goldman Sachs 47th Annual Global Healthcare Conference. This event is significant for stakeholders in the healthcare sector, providing insights into Ardent Health's strategic direction. Further details about the company's agenda at the conference have not been disclosed.
Read more →-ARDT
Jun 2, 2026Ardent Health Appoints Dave Caspers as CEO
Ardent Health has appointed Dave Caspers as its new CEO. This leadership change is expected to steer the company towards its future goals. Further details regarding Caspers' vision and plans for Ardent Health were not disclosed in the announcement.
Read more →-ARDT
Jun 2, 2026Ardent Health Appoints Dave Caspers as CEO Mr. Caspers brings decades of operational expertise and a deep understanding of Ardent Health's mission to enhance healthcare access and service Transition positions Ardent Heal
Ardent Health has appointed Dave Caspers as its new President and CEO, effective immediately, following the departure of Marty Bonick. Caspers brings extensive operational experience, having previously served as the company's COO, and is expected to drive the company's focus on operational excellence and long-term growth. The leadership transition aims to enable Ardent Health to continue enhancing the quality of care delivered in mid-sized urban communities. Despite reaffirming its financial targets for 2026, the company acknowledges recent softness in volumes across its portfolio, which may present challenges during this transition phase.
Read more →-ARDT
May 14, 2026Ardent Health and Fujifilm Partner to Deliver Synapse Enterprise Imaging Across Radiology and Cardiology Throughout All Facilities
Ardent Health has partnered with Fujifilm to implement Synapse Enterprise Imaging across its radiology and cardiology departments. This collaboration aims to enhance imaging capabilities throughout all Ardent facilities. The initiative is expected to improve patient care and streamline operations, although specific details on implementation and expected outcomes are limited.
Read more →-ARDT
May 5, 2026Ardent Health Reports First Quarter 2026 Results
Ardent Health has reported its financial results for the first quarter of 2026. The article does not provide specific details regarding revenue, expenses, or other financial metrics. It appears to be a preliminary announcement without in-depth analysis or commentary.
Read more →-ARDT
May 5, 2026Ardent Health Reports First Quarter 2026 Results Brentwood, Tenn. (
Ardent Health, Inc. reported its financial results for the first quarter of 2026, achieving a total revenue of $1.60 billion, which represents a 7.0% increase compared to the previous year. The company also noted a 26.3% rise in adjusted EBITDA to $124 million. However, there was a slight decrease in total admissions by 1.1%, attributed to external factors such as severe weather. Despite these challenges, Ardent has reaffirmed its full-year guidance for 2026, maintaining projected revenues and adjusted EBITDA.
Read more →-ARDT
Apr 16, 2026Ardent Health Announces First Quarter 2026 Results Conference Call and Webcast Date
Ardent Health has announced the date for its first quarter 2026 results conference call and webcast. This event will provide insights into the company's financial performance and strategic direction. Details regarding the time and access to the call will be shared in due course.
Read more →-ARDT
Mar 4, 2026Ardent Health Reports Fourth Quarter 2025 Results Brentwood, Tenn. (
Ardent Health, Inc. reported mixed financial results for the fourth quarter of 2025, with total revenue declining by 0.1% year-over-year, amounting to $1.61 billion. While adjusted EBITDA and net income experienced significant decreases compared to the previous year, the company announced a full-year revenue growth of 6.0% and an adjusted EBITDA increase of 9.3%. Operating cash flow saw a notable rise, up 87% from the prior year. Ardent has provided guidance for the upcoming year, projecting total revenue between $6.4 billion and $6.7 billion.
Read more →-ARDT
Nov 18, 2025▲ +5.1%on this news
Ardent Health Announces $50 Million Share Repurchase Program Authorization BRENTWOOD, Tenn. (
Ardent Health (NYSE ARDT) has authorized a $50 million share repurchase program, reflecting confidence in its business strength and commitment to shareholder value. The program aims to enhance financial flexibility while allowing the company to continue pursuing strategic growth, including possible mergers and acquisitions. With a strong cash position of $609 million, Ardent is well-equipped to act on attractive market opportunities.
Read more →-ARDT
Nov 12, 2025Ardent Health Reports Third Quarter 2025 Results Brentwood, Tenn. (
Ardent Health, Inc. reported its financial results for the third quarter of 2025, revealing total revenues of $1.58 billion, which reflects an 8.8% year-over-year growth. However, the company incurred a net loss of $23 million, contrasting with a net income in the same quarter the previous year. Despite these challenges, adjusted EBITDA experienced a notable increase of 46.3%. The financial results were impacted by non-recurring items, including reductions in revenue due to adjustments in accounting estimates and increases in liability reserves.
Read more →-ARDT
Sep 22, 2025Ardent Announces Successful Amendment and Extension of Term Loan Facility BRENTWOOD, Tenn. (
Ardent Health has successfully amended and extended its Term Loan Facility totaling $777.5 million, reducing the interest rate from SOFR plus 2.75% to SOFR plus 2.25%. This change extends the maturity and is anticipated to save the company around $3.9 million in interest expenses annually. The CFO expressed that these adjustments improve financial flexibility and support continued investments in healthcare across their communities. Ardent operates a significant healthcare system with 30 acute care hospitals and 280 care sites throughout six states.
Read more →-ARDT
Aug 5, 2025Ardent Health Reports Second Quarter 2025 Results Brentwood, Tenn. (
Ardent Health, Inc. reported its second quarter results for 2025, showing strong financial growth. Total revenue grew by 11.9% year-over-year to $1.65 billion, with net income nearly doubling from the previous year to $73 million. Adjusted EBITDA also saw a significant increase of 38.9%, reaching $170 million. The company reaffirmed its financial guidance for the full year of 2025, expecting total revenue between $6.2 billion and $6.45 billion.
Read more →-ARDT
May 6, 2025Ardent Health Reports First Quarter 2025 Results Brentwood, Tenn. (
Ardent Health Partners, Inc. reported a 4.0% year-over-year increase in total revenue for the first quarter of 2025, reaching $1.50 billion, with net income rising to $41 million. This growth was primarily driven by increased admissions and net patient service revenue per adjusted admission. However, the company faced a revenue drop of over $10 million due to the transfer of certain oncology and infusion services to an academic health partner. Ardent reaffirmed its full-year 2025 guidance, indicating optimistic projections for future performance.
Read more →-ARDT
Apr 3, 2025Ardent Health Appoints Robert DeMichiei to Board of Directors BRENTWOOD, Tenn. (
Ardent Health has appointed Robert A. DeMichiei to its Board of Directors. DeMichiei, who has over 30 years of experience in financial strategy and healthcare operations, previously served as CFO at the University of Pittsburgh Medical Center. His appointment is seen as a strategic move to enhance Ardent Health's governance and operational excellence as the company continues its growth trajectory.
Read more →-ARDT
Mar 31, 2025Ardent Health Announces Appointment of Chief Operating Officer and Senior Leadership Promotions BRENTWOOD, Tenn. (
Ardent Health has appointed Dave Caspers as Chief Operating Officer to enhance operational efficiency across its 30 hospitals and 280 care sites. Caspers, who has extensive experience in health system operations and retail healthcare, will drive strategic growth initiatives for the company. Additionally, Ardent announced senior leadership promotions for Anika Gardenhire, Rebecca Kirkham, and Reed Smith, aimed at advancing the company’s digital transformation and consumer engagement efforts.
Read more →-ARDT
Feb 26, 2025Brentwood, Tenn.
Ardent Health Partners, Inc. reported strong financial results for Q4 2024, with a 19% increase in total revenue and a remarkable 213% growth in Adjusted EBITDA. The positive results were bolstered by a significant $94 million recognized from the New Mexico state directed payment program. Furthermore, Ardent Health announced its financial guidance for 2025, projecting continued growth in revenue and Adjusted EBITDA. The company also made strategic moves including the acquisition of 18 urgent care clinics aimed at enhancing its ambulatory services and expanding its market presence.
Read more →-ARDT
Jan 13, 2025jpmpresentatio January 2025 Investor Presentation Important disclaimers Forward-Looking Statements Certain statements contained in this presentation regarding future operating results or performance or business plans or
Ardent Health Partners, Inc. released an investor presentation that highlights future operating results and performance forecasts, while emphasizing that these projections are forward-looking statements. Various risks and uncertainties are stated, such as changes in governmental healthcare programs, labor shortages, and competition in the healthcare industry, which could significantly affect the actual outcomes from management's expectations. The document also clarifies the non-GAAP financial measures it utilizes for evaluation, such as Adjusted EBITDA, which may not be comparable to similar measures used by other companies.
Read more →-ARDT
Nov 6, 2024▼ -9.9%on this news
Ardent Health Reports Third Quarter 2024 Results Brentwood, Tenn. (
Ardent Health Partners, Inc. reported its third quarter results for 2024, showing positive financial growth. Total revenue reached $1.45 billion, a 5.2% increase from the previous year. Adjusted EBITDA saw a notable 15.3% rise, driven by higher patient volumes and strategic optimizations. However, the company faced challenges, including a reduction in revenue due to service transfers and adjustments in net income guidance. Overall, the outlook remains positive with increased revenue projections for the full year.
Read more →-ARDT
Aug 14, 2024Ardent Health Reports Second Quarter 2024 Results BRENTWOOD, Tenn. (
Ardent Health Partners, Inc. reported strong financial results for the second quarter of 2024, with total revenue increasing by 7.5% to $1.47 billion and adjusted EBITDA rising by 20%. The net income attributable to the company was $43 million, an improvement from the previous year. Following a successful IPO that raised $209 million, Ardent is positioned for continued growth, focusing on expanding services in its markets despite some declines in certain surgery volumes. The company anticipates strong financial guidance for the remainder of the year, aiming for a 6% to 9% revenue growth.
Read more →Competitive Position
How ARDT ranks across every disease it competes inCompetitive Position is a premium feature
See how ARDT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial